Antineoplastic Agents - Therapeutic use
Research News and Information

Saturday, November 21, 2009

Allogeneic hematopoietic cell transplantation (allogeneic HCT) for treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL).

13 Dec 2009 BACKGROUND: Allogeneic hematopoietic cell transplant (HCT) with best available donor for children with Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL) has previously been considered standard practice. Since the introduction of ... Read more...

Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program.

13 Dec 2009 BACKGROUND: Ispinesib is a highly specific inhibitor of kinesin spindle protein (KSP, HsEg5), a mitotic kinesin required for separation of the spindle poles. Here we report the activity of ispinesib against the in vitro and in vivo panels of the ... Read more...

Continuous and intermittent dosing of lonafarnib potentiates the therapeutic efficacy of docetaxel on preclinical human prostate cancer models.

29 Nov 2009 Lonafarnib is a potent, selective farnesyltransferase inhibitor (FTI) undergoing clinical studies for the treatment of solid tumors and hematological malignancies. Preclinically, a number of FTIs, including lonafarnib, interact with taxanes to ... Read more...

Latest indexed articles for 'Antineoplastic Agents - Therapeutic use'

These are the very latest articles for this heading:

• Allogeneic hematopoietic cell transplantation (allogeneic HCT) for treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). 13 Dec 2009
• Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program. 13 Dec 2009
• Continuous and intermittent dosing of lonafarnib potentiates the therapeutic efficacy of docetaxel on preclinical human prostate cancer models. 29 Nov 2009
• Sphingosine kinase 1 inhibition sensitizes hormone-resistant prostate cancer to docetaxel. 29 Nov 2009
• Sustained first remission in an adolescent with hepatosplenic T-cell lymphoma treated with T-cell leukemia induction, nucleoside analog-based consolidation, and early hematopoietic stem cell transplant. 29 Nov 2009
• Enhanced expression of Annexin A4 in clear cell carcinoma of the ovary and its association with chemoresistance to carboplatin. 13 Nov 2009
• Antitumor activity of delimotecan against human metastatic melanoma: pharmacokinetics and molecular determinants. 13 Nov 2009
• Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer. 13 Nov 2009
• Radiotherapy in conjunction with 7-hydroxystaurosporine: a multimodal approach with tumor pO2 as a potential marker of therapeutic response. 30 Oct 2009
• HER2 Intermediate Breast Cancers. 30 Oct 2009
• Have we reached a plateau in adjuvant breast cancer therapy? 22 Oct 2009
• Characteristics of children enrolled in treatment trials for NF1-related plexiform neurofibromas. 18 Oct 2009
• Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. 13 Oct 2009
• Progression-free survival remains debatable endpoint in cancer trials. 12 Oct 2009
• Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer. 11 Oct 2009
• Correlation of enzyme-inducing anticonvulsant use with outcome of patients with glioblastoma. 11 Oct 2009
• Cancer research. Looking for a target on every tumor. 7 Oct 2009
• Analysis of risk factors for central venous port failure in cancer patients. 5 Oct 2009
• A case of bone, lung, pleural and liver metastases from renal cell carcinoma which responded remarkably well to zoledronic acid monotherapy. 4 Oct 2009
• Adoptive immunotherapy with liver allograft-derived lymphocytes induces anti-HCV activity after liver transplantation in humans and humanized mice. 29 Sep 2009

See a longer list of these articles.

Technical information about 'Antineoplastic Agents'

Definition: Substances that inhibit or prevent the proliferation of NEOPLASMS.

Registry Number: 0

Descriptor UI: D000970

Alternative terms: Antineoplastic Agents; Agents, Antineoplastic; Antineoplastics; Antitumor Drugs; Drugs, Antitumor; Antineoplastic Drugs; Drugs, Antineoplastic; Antitumor Agents; Agents, Antitumor;

Related Mesh Headings: Cytotoxins; Infusions, Intra-Arterial; Chemotherapy, Cancer, Regional Perfusion; Tumor Lysis Syndrome; Chemoembolization, Therapeutic; Anticarcinogenic Agents;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D27.505.954.248;

Technical Notes: /admin: various administration procedures are available, as CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; CHEMOEMBOLIZATION, THERAPEUTIC and INFUSIONS, INTRA-ARTERIAL; for combined anticancer agents, ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS is available; Manual 24.4.2.1+